Frank Watanabe

Frank Watanabe is the president and chief executive officer of Arcutis Biotherapeutics, a commercial-stage dermatology company based in the Los Angeles area. He has served as Arcutis’s president since 2016 and as chief executive since 2017, building the company from a handful of employees into a public, multi-product commercial business with one of the industry’s deeper dermatology pipelines.

Watanabe came to biopharmaceuticals after a first career in government. He had a career in national security in the federal government and was a commissioned officer in the US Navy Reserve for 25 years before joining Eli Lilly and discovering what he describes as the mission-driven pull of the industry. He spent eight years as an executive at Amgen, where he worked on the development of Repatha and Aimovig and on the US marketing of Enbrel in dermatology and rheumatology, then served as vice president of strategy and corporate development at Kythera Biopharmaceuticals and as co-founder and chief operating officer of the cardiovascular company Kanan Therapeutics. He holds a master’s degree in national security studies and a bachelor’s degree in international relations, both from Georgetown University, and serves as vice chairman of BIO, the biotechnology industry’s trade organization.

Watanabe appeared on Open Door Salon alongside Josh Fessel, a physician-scientist and former NIH translational-medicine leader, for a candid conversation on how the biopharmaceutical industry can survive and adapt in an unusually uncertain market. Watanabe’s central message to struggling and emerging chief executives was disciplined and blunt: capital is survival, and the companies that endure are the ones that treat it that way.

He argued that the era of the fast-follower “me-too” drug is closing as Chinese competitors out-execute it, that investors have grown far more discriminating, and that a “divot” cut into basic research today will surface as a painful gap in the commercial pipeline eight to ten years out. As vice chairman of BIO, he urged smaller companies, which lack the Washington presence of a large pharma, to organize collectively rather than be buffeted by forces they cannot individually influence.